| Trial ID: | L6492 |
| Source ID: | NCT01904383
|
| Associated Drug: |
Trazenta
|
| Title: |
PMS of Trazenta on the Long-term Use as Add-on Therapy
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01904383/results
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Trazenta
|
| Outcome Measures: |
Primary: Percentage of Participants With Drug Related Adverse Events, Percentage of participants with drug related adverse events., From first drug administration until last drug administration, up to approximately 156 weeks. | Secondary: The Mean Change From Baseline to Last Observation of the Treatment Period in Haemoglobin A1c (HbA1c), The mean change from baseline to last observation of the treatment period in Haemoglobin A1c (HbA1c)., Baseline (before administration of treatment) and last observation of the treatment period; up to 156 weeks.
|
| Sponsor/Collaborators: |
Sponsor: Boehringer Ingelheim | Collaborators: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
4057
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2013-07-01
|
| Completion Date: |
2018-10-04
|
| Results First Posted: |
2019-10-02
|
| Last Update Posted: |
2019-10-02
|
| Locations: |
Multiple Locations, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT01904383
|
